Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: The emerging gene portrait of the mesothelioma phenotype

PLoS ONE

Volumn 4, Issue 8, 2009, Pages

  Røe, Oluf Dimitri ^a,b   Anderssen, Endre ^b   Helge, Eli ^b   Pettersen, Caroline Hild ^b   Olsen, Karina Standahl ^c   Sandeck, Helmut ^a   Haaverstad, Rune ^d   Lundgren, Steinar ^a   Larsson, Erik ^b  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; DNA; PROTEIN NME1; PROTEIN NME2; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CANCER TISSUE; CELL COMMUNICATION; CELL CYCLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; DNA REPAIR; DNA REPLICATION; FEMALE; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE OVEREXPRESSION; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNE SYSTEM; MALE; MICROARRAY ANALYSIS; MITOSIS; PHENOTYPE; PLEURA; PLEURA MESOTHELIOMA; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; APOPTOSIS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; MESOTHELIOMA; METASTASIS; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PLEURA TUMOR; VASCULARIZATION;

ADOLESCENT; ADULT; APOPTOSIS; CELL CYCLE; CIRCADIAN RHYTHM; DNA REPAIR; FEMALE; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; MITOSIS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; PLEURAL NEOPLASMS;

EID: 68449088127     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0006554     Document Type: Article

References (86)

1. Robinson BW, Musk AW, Lake RA (2005) Malignant mesothelioma. Lancet 366: 397-408.
2. Baas P (2005) Chemotherapy for malignant mesothelioma. Lung Cancer 49 Suppl 1: S61-64.
3. Bridda A, Padoan I, Mencarelli R, Frego M (2007) Peritoneal mesothelioma: a review. MedGenMed 9: 32.
4. Boutin C, Rey F (1993) Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1: Diagnosis. Cancer 72: 389-393.
5. Lindholm PM, Salmenkivi K, Vauhkonen H, Nicholson AG, Anttila S, et al. (2007) Gene copy number analysis in malignant pleural mesothelioma using oligonucleotide array CGH. Cytogenet Genome Res 119: 46-52.
6. Musti M, Kettunen E, Dragonieri S, Lindholm P, Cavone D, et al. (2006) Cytogenetic and molecular genetic changes in malignant mesothelioma. Cancer Genet Cytogenet 170: 9-15.
7. Roe OD, Anderssen E, Sandeck H, Christensen T, Larsson E, et al. (2009) Malignant pleural mesothelioma: Genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets. Lung Cancer.
8. Roe OD, Creaney J, Lundgren S, Larsson E, Sandeck H, et al. (2008) Mesothelin-related predictive and prognostic factors in malignant mesothelioma: A nested case-control study. Lung Cancer.
9. Malard V, Berenguer F, Prat O, Ruat S, Steinmetz G, et al. (2007) Global gene expression profiling in human lung cells exposed to cobalt. BMC Genomics 8: 147.
10. Wang NS (1985) Anatomy and physiology of the pleural space. Clin Chest Med 6: 3-16.
11. Steiglitz BM, Keene DR, Greenspan DS (2002) PCOLCE2 encodes a functional procollagen C-proteinase enhancer (PCPE2) that is a collagen-binding protein differing in distribution of expression and post-translational modification from the previously described PCPE1. J Biol Chem 277: 49820-49830.
12. Langsenlehner U, Renner W, Yazdani-Biuki B, Eder T, Wascher TC, et al. (2006) Integrin alpha-2 and beta-3 gene polymorphisms and breast cancer risk. Breast Cancer Res Treat 97: 67-72.
13. FitzGerald LM, Patterson B, Thomson R, Polanowski A, Quinn S, et al. (2009) Identification of a prostate cancer susceptibility gene on chromosome 5p13q12 associated with risk of both familial and sporadic disease. Eur J Hum Genet 17: 368-377.
14. Rustum YM, Takita H, Gomez G (1980) The design of cancer chemotherapy: metabolic modulation and cellular de novo versus salvage metabolism. Antibiot Chemother 28: 86-93.
15. Kinsella AR, Haran MS (1991) Decreasing sensitivity to cytotoxic agents parallels increasing tumorigenicity in human fibroblasts. Cancer Res 51: 1855-1859.
16. Rahman L, Voeller D, Rahman M, Lipkowitz S, Allegra C, et al. (2004) Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. Cancer Cell 5: 341-351.
17. de Angelis PM, Fjell B, Kravik KL, Haug T, Tunheim SH, et al. (2004) Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil. Int J Oncol 24: 1279-1288.
18. Mazurek S, Grimm H, Boschek CB, Vaupel P, Eigenbrodt E (2002) Pyruvate kinase type M2: a crossroad in the tumor metabolome. Br J Nutr 87 Suppl 1: S23-29.
19. Kumar Y, Tapuria N, Kirmani N, Davidson BR (2007) Tumour M2-pyruvate kinase: a gastrointestinal cancer marker. Eur J Gastroenterol Hepatol 19: 265-276.
20. Hartsough MT, Clare SE, Mair M, Elkahloun AG, Sgroi D, et al. (2001) Elevation of breast carcinoma Nm23-H1 metastasis suppressor gene expression and reduced motility by DNA methylation inhibition. Cancer Res 61: 2320-2327.
21. Gonzalez S, Klatt P, Delgado S, Conde E, Lopez-Rios F, et al. (2006) Oncogenic activity of Cdc6 through repression of the INK4/ARF locus. Nature 440: 702-706.
22. Reimer D, Sadr S, Wiedemair A, Goebel G, Concin N, et al. (2006) Expression of the E2F family of transcription factors and its clinical relevance in ovarian cancer. Ann N Y Acad Sci 1091: 270-281.
23. Giacinti C, Giordano A (2006) RB and cell cycle progression. Oncogene 25: 5220-5227.
24. Kamrul HM, Wadhwa R, Kaul SC (2007) CARF binds to three members (ARF, p53, and HDM2) of the p53 tumor-suppressor pathway. Ann N Y Acad Sci 1100: 312-315.
25. Hashimoto K, Araki K, Osaki M, Nakamura H, Tomita K, et al. (2004) MCM2 and Ki-67 expression in human lung adenocarcinoma: prognostic implications. Pathobiology 71: 193-200.
26. Soling A, Sackewitz M, Volkmar M, Schaarschmidt D, Jacob R, et al. (2005) Minichromosome maintenance protein 3 elicits a cancer-restricted immune response in patients with brain malignancies and is a strong independent predictor of survival in patients with anaplastic astrocytoma. Clin Cancer Res 11: 249-258.
27. Xu J, Zhang S, You C, Huang S, Cai B, et al. (2007) Expression of human MCM6 and DNA Topo II alpha in craniopharyngiomas and its correlation with recurrence of the tumor. J Neurooncol 83: 183-189.
28. Ha SA, Shin SM, Namkoong H, Lee H, Cho GW, et al. (2004) Cancer-associated expression of minichromosome maintenance 3 gene in several human cancers and its involvement in tumorigenesis. Clin Cancer Res 10: 8386-8395.
29. Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, et al. (2006) Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 98: 472-482.
30. Salabat MR, Melstrom LG, Strouch MJ, Ding XZ, Milam BM, et al. (2008) Geminin is overexpressed in human pancreatic cancer and downregulated by the bioflavanoid apigenin in pancreatic cancer cell lines. Mol Carcinog.
31. Acevedo-Duncan M, Patel R, Whelan S, Bicaku E (2002) Human glioma PKC-iota and PKC-betaII phosphorylate cyclin-dependent kinase activating kinase during the cell cycle. Cell Prolif 35: 23-36.
32. Regala RP, Weems C, Jamieson L, Khoor A, Edell ES, et al. (2005) Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer. Cancer Res 65: 8905-8911.
33. Xu L, Deng X (2006) Suppression of cancer cell migration and invasion by protein phosphatase 2A through dephosphorylation of mu- and m-calpains. J Biol Chem 281: 35567-35575.
34. Larochelle S, Merrick KA, Terret ME, Wohlbold L, Barboza NM, et al. (2007) Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells. Mol Cell 25: 839-850.
35. Castedo M, Perfettini JL, Roumier T, Kroemer G (2002) Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe. Cell Death Differ 9: 1287-1293.
36. Yu J, Guo QL, You QD, Zhao L, Gu HY, et al. (2007) Gambogic acid-induced G2/M phase cell-cycle arrest via disturbing CDK7-mediated phosphorylation of CDC2/p34 in human gastric carcinoma BGC-823 cells. Carcinogenesis 28: 632-638.
37. Vivo C, Levy F, Pilatte Y, Fleury-Feith J, Chretien P, et al. (2001) Control of cell cycle progression in human mesothelioma cells treated with gamma interferon. Oncogene 20: 1085-1093.
38. Turnell AS, Stewart GS, Grand RJ, Rookes SM, Martin A, et al. (2005) The APC/C and CBP/p300 cooperate to regulate transcription and cell-cycle progression. Nature 438: 690-695.
39. Camasses A, Bogdanova A, Shevchenko A, Zachariae W (2003) The CCT chaperonin promotes activation of the anaphase-promoting complex through the generation of functional Cdc20. Mol Cell 12: 87-100.
40. Prasanth SG, Prasanth KV, Stillman B (2002) Orc6 involved in DNA replication, chromosome segregation, and cytokinesis. Science 297: 1026-1031.
41. Warner SL, Gray PJ, Von Hoff DD (2006) Tubulin-associated drug targets: Aurora kinases, Polo-like kinases, and others. Semin Oncol 33: 436-448.
42. Kauffmann A, Rosselli F, Lazar V, Winnepenninckx V, Mansuet-Lupo A, et al. (2008) High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene 27: 565-573.
43. Gery S, Koeffler HP (2007) The role of circadian regulation in cancer. Cold Spring Harb Symp Quant Biol 72: 459-464.
44. Gery S, Komatsu N, Kawamata N, Miller CW, Desmond J, et al. (2007) Epigenetic silencing of the candidate tumor suppressor gene Per1 in non-small cell lung cancer. Clin Cancer Res 13: 1399-1404.
45. Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ, et al. (2005) Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis 26: 1241-1246.
46. Xiang S, Coffelt SB, Mao L, Yuan L, Cheng Q, et al. (2008) Period-2: a tumor suppressor gene in breast cancer. J Circadian Rhythms 6: 4.
47. Teboul M, Guillaumond F, Grechez-Cassiau A, Delaunay F (2008) The nuclear hormone receptor family round the clock. Mol Endocrinol 22: 2573-2582.
48. Bertolucci C, Cavallari N, Colognesi I, Aguzzi J, Chen Z, et al. (2008) Evidence for an overlapping role of CLOCK and NPAS2 transcription factors in liver circadian oscillators. Mol Cell Biol 28: 3070-3075.
49. Wood PA, Du-Quiton J, You S, Hrushesky WJ (2006) Circadian clock coordinates cancer cell cycle progression, thymidylate synthase, and 5-fluorouracil therapeutic index. Mol Cancer Ther 5: 2023-2033.
50. Gorbacheva VY, Kondratov RV, Zhang R, Cherukuri S, Gudkov AV, et al. (2005) Circadian sensitivity to the chemotherapeutic agent cyclophosphamide depends on the functional status of the CLOCK/BMAL1 transactivation complex. Proc Natl Acad Sci U S A 102: 3407-3412.
51. Tozlu-Kara S, Roux V, Andrieu C, Vendrell J, Vacher S, et al. (2007) Oligonucleotide microarray analysis of estrogen receptor alpha-positive postmenopausal breast carcinomas: identification of HRPAP20 and TIMELESS as outstanding candidate markers to predict the response to tamoxifen. J Mol Endocrinol 39: 305-318.
52. Towne JE, Garka KE, Renshaw BR, Virca GD, Sims JE (2004) Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs. J Biol Chem 279: 13677-13688.
53. Kanehisa M, Araki M, Goto S, Hattori M, Hirakawa M, et al. (2008) KEGG for linking genomes to life and the environment. Nucleic Acids Res 36: D480-484.
54. Briassouli P, Chan F, Savage K, Reis-Filho JS, Linardopoulos S (2007) Aurora-A regulation of nuclear factor-kappaB signaling by phosphorylation of IkappaBalpha. Cancer Res 67: 1689-1695.
55. Lopez-Rios F, Chuai S, Flores R, Shimizu S, Ohno T, et al. (2006) Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 66: 2970-2979.
56. Mountzios G, Terpos E, Dimopoulos MA (2008) Aurora kinases as targets for cancer therapy. Cancer Treat Rev 34: 175-182.
57. Ozdemir F, Akdogan R, Aydin F, Reis A, Kavgaci H, et al. (2006) The effects of VEGF and VEGFR-2 on survival in patients with gastric cancer. J Exp Clin Cancer Res 25: 83-88.
58. Ohta Y, Shridhar V, Bright RK, Kalemkerian GP, Du W, et al. (1999) VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 81: 54-61.
59. Tian XL, Kadaba R, You SA, Liu M, Timur AA, et al. (2004) Identification of an angiogenic factor that when mutated causes susceptibility to Klippel-Trenaunay syndrome. Nature 427: 640-645.
60. Jacquemont C, Taniguchi T (2007) Proteasome function is required for DNA damage response and fanconi anemia pathway activation. Cancer Res 67: 7395-7405.
61. Ogiso Y, Tomida A, Lei S, Omura S, Tsuruo T (2000) Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Res 60: 2429-2434.
62. Wang JC, Su CC, Xu JB, Chen LZ, Hu XH, et al. (2007) Novel microdeletion in the transforming growth factor beta type II receptor gene is associated with giant and large cell variants of nonsmall cell lung carcinoma. Genes Chromosomes Cancer 46: 192-201.
63. Wei T, Geiser AG, Qian HR, Su C, Helvering LM, et al. (2007) DNA microarray data integration by ortholog gene analysis reveals potential molecular mechanisms of estrogen-dependent growth of human uterine fibroids. BMC Womens Health 7: 5.
64. Belogubova EV, Togo AV, Karpova MB, Kuligina E, Buslova KG, et al. (2004) A novel approach for assessment of cancer predisposing roles of GSTM1 and GSTT1 genes: use of putatively cancer resistant elderly tumor-free smokers as the referents. Lung Cancer 43: 259-266.
65. Singh M, Shah PP, Singh AP, Ruwali M, Mathur N, et al. (2008) Association of genetic polymorphisms in glutathione S-transferases and susceptibility to head and neck cancer. Mutat Res 638: 184-194.
66. Rihn BH, Mohr S, McDowell SA, Binet S, Loubinoux J, et al. (2000) Differential gene expression in mesothelioma. FEBS Lett 480: 95-100.
67. Kettunen E, Nissen AM, Ollikainen T, Taavitsainen M, Tapper J, et al. (2001) Gene expression profiling of malignant mesothelioma cell lines: cDNA array study. Int J Cancer 91: 492-496.
68. Singhal S, Wiewrodt R, Malden LD, Amin KM, Matzie K, et al. (2003) Gene expression profiling of malignant mesothelioma. Clin Cancer Res 9: 3080-3097.
69. Mohr S, Keith G, Galateau-Salle F, Icard P, Rihn BH (2004) Cell protection, resistance and invasiveness of two malignant mesotheliomas as assessed by 10K-microarray. Biochim Biophys Acta 1688: 43-60.
70. Mohr S, Bottin MC, Lannes B, Neuville A, Bellocq JP, et al. (2004) Microdissection, mRNA amplification and microarray: a study of pleural mesothelial and malignant mesothelioma cells. Biochimie 86: 13-19.
71. Hoang CD, D'Cunha J, Kratzke MG, Casmey CE, Frizelle SP, et al. (2004) Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest 125: 1843-1852.
72. Kettunen E, Nicholson AG, Nagy B, Wikman H, Seppanen JK, et al. (2005) L1CAM, INP10, P-cadherin, tPA and ITGB4 over-expression in malignant pleural mesotheliomas revealed by combined use of cDNA and tissue microarray. Carcinogenesis 26: 17-25.
73. Sun X, Wei L, Liden J, Hui G, Dahlman-Wright K, et al. (2005) Molecular characterization of tumour heterogeneity and malignant mesothelioma cell differentiation by gene profiling. J Pathol 207: 91-101.
74. Dejmek A, Brockstedt U, Hjerpe A (1997) Optimization of a battery using nine immunocytochemical variables for distinguishing between epithelial mesothelioma and adenocarcinoma. APMIS 105: 889-894.
75. Hassan R, Ho M (2008) Mesothelin targeted cancer immunotherapy. Eur J Cancer 44: 46-53.
76. Lugli A, Forster Y, Haas P, Nocito A, Bucher C, et al. (2003) Calretinin expression in human normal and neoplastic tissues: a tissue microarray analysis on 5233 tissue samples. Hum Pathol 34: 994-1000.
77. Thickett DR, Armstrong L, Millar AB (1999) Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions. Thorax 54: 707-710.
78. Krause DS, Theise ND, Collector MI, Henegariu O, Hwang S, et al. (2001) Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell 105: 369-377.
79. Lama VN, Phan SH (2006) The extrapulmonary origin of fibroblasts: stem/ progenitor cells and beyond. Proc Am Thorac Soc 3: 373-376.
80. Boquest AC, Shahdadfar A, Brinchmann JE, Collas P (2006) Isolation of stromal stem cells from human adipose tissue. Methods Mol Biol 325: 35-46.
81. Lu C, Bonome T, Li Y, Kamat AA, Han LY, et al. (2007) Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res 67: 1757-1768.
82. Zanazzi C, Hersmus R, Veltman IM, Gillis AJ, van Drunen E, et al. (2007) Gene expression profiling and gene copy-number changes in malignant mesothelioma cell lines. Genes Chromosomes Cancer 46: 895-908.
83. Reiner A, Yekutieli D, Benjamini Y (2003) Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 19: 368-375.
84. Benjamini Y, Hochberg Y (1995) Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society 57: 289-300.
85. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25-29.
86. Gidskehaug L, Anderssen E, Flatberg A, Alsberg BK (2007) A framework for significance analysis of gene expression data using dimension reduction methods. BMC Bioinformatics 8: 346.